Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542035 · ClinicalTrials.gov registry record · Phase 2
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT00542035 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 103 participants.
The verdict
NCT00542035, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain either perioperatively or postoperatively in a third molar extraction pain model, and to further evaluate the drug's safety. Approximately 150 subjects from the US will be enrolled in this study.
Interventions
- DRUG ARRY-371797, p38 inhibitor; oral
- DRUG Placebo; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2007-11-11 |
| Est. Completion | 2008-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00542035
The ClinicalTrials.gov registry entry for NCT00542035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ARRY-371797, p38 inhibitor; oral is the first listed.
NCT00542035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00542035 about?
NCT00542035 is a clinical study titled "A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction". This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain either perioperatively or postoperatively in a third molar extraction pain model, and to further evaluate the drug's safety. Approximately 150 subjects from the US will be enrolled in this s...
What is the current status of trial NCT00542035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2007-11-11. Estimated completion is 2008-02-11.
What interventions are being tested in trial NCT00542035?
The interventions under investigation include: ARRY-371797, p38 inhibitor; oral (DRUG), Placebo; oral (DRUG).
Who is sponsoring clinical trial NCT00542035?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.